ICLR
What one share of ICON holds
Services – Commercial Physical and Biological Research
ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations.
ICON’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $104.49 |
|---|---|
| Profit | $2.90 |
| Capex (buildings and equipment) | $2.21 |
| Free cash flow | $10.92 |
| Cash and investments | $8.45 |
| Debt | $37.52 |
| Book value | $120.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2008 | $14.86 | $1.30 | $1.17 | $0.23 | — | $7.84 |
| 2009 | $14.82 | $1.57 | $0.56 | $3.69 | — | $9.70 |
| 2010 | $14.84 | $1.44 | $0.51 | $0.93 | — | $11.12 |
| 2011 | $15.49 | $0.37 | $0.58 | −$0.25 | — | $11.33 |
| 2012 | $18.44 | $0.92 | $0.51 | $1.37 | — | $12.52 |
| 2013 | $21.46 | $1.65 | $0.47 | $3.08 | — | $14.79 |
| 2014 | $23.81 | $2.73 | $0.52 | $2.17 | — | $15.81 |
| 2015 | $26.12 | $3.97 | $0.82 | $3.80 | — | $13.88 |
| 2016 | $29.54 | $4.65 | $0.76 | $3.84 | — | $17.33 |
| 2017 | $32.06 | $5.13 | $0.82 | $6.17 | — | $22.02 |
| 2018 | $47.38 | $5.89 | $0.88 | $4.02 | — | $25.09 |
| 2019 | $51.64 | $6.79 | $0.72 | $6.88 | — | $30.18 |
| 2020 | $52.50 | $6.15 | $0.77 | $9.89 | — | $35.05 |
| 2021 | $80.52 | $2.25 | $1.38 | $10.80 | — | $98.91 |
| 2022 | $93.87 | $6.13 | $1.72 | $5.11 | — | $104.34 |
| 2023 | $97.38 | $6.70 | $1.70 | $12.34 | — | $111.66 |
| 2024 | $98.62 | $8.90 | $2.02 | $13.47 | — | $116.91 |
| 2025 | $104.49 | $2.90 | $2.21 | $10.92 | — | $120.07 |